An Open-Label Study to Assess the Pharmacokinetics With Maximal Use of Luliconazole Cream 1% in Pediatric Patients With Moderate to Severe Tinea Pedis or Tinea Cruris

Next Previous
Trial Profile

An Open-Label Study to Assess the Pharmacokinetics With Maximal Use of Luliconazole Cream 1% in Pediatric Patients With Moderate to Severe Tinea Pedis or Tinea Cruris

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 May 2017

At a glance

  • Drugs Luliconazole (Primary)
  • Indications Tinea cruris; Tinea pedis
  • Focus Pharmacokinetics
  • Sponsors Valeant Pharmaceuticals International

    • Most Recent Events

    • 26 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 12 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top